Prelude Capital Management, LLC Immuno Gen, Inc. Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $704,500 - $1.69 Million	56,541 Added 55.81%	157,856 $4.68 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $351,305 - $495,418	24,933 Added 32.64%	101,315 $1.61 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $286,432 - $1.53 Million	76,382 New	76,382 $1.44 Million
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $7,048 - $10,763	-3,175 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $5,715 - $10,477	3,175 New	3,175 $7,000
Q2 2018 Aug 14, 2018	SELL	$9.52 - $12.15 $20,944 - $26,730	-2,200 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$6.7 - $12.95 $14,740 - $28,490	2,200 New	2,200 $23,000
Q4 2017 Feb 14, 2018	SELL	$5.07 - $7.92 $22,815 - $35,640	-4,500 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $24,300 - $38,115	4,500	4,500 $34,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.